Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1CNS 1

Conditions

Hematologic Neoplasms 2Cholangiocarcinoma 2Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Granuloma, Plasma Cell 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 14fludarabine 10fludarabine phosphate 8Whole-Body Irradiation 7thymoglobulin 5Thiotepa 5Tacrolimus 5Stem Cell Transplantation 5Standard of Care 5Practice Guidelines as Topic 5Nivolumab 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Azacitidine 5venetoclax 4Radiotherapy 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 4Rituximab 3Mesna 3Leucovorin 3Dexamethasone 3Calcium Dobesilate 3Alemtuzumab 3ruxolitinib 2ceritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hematologic Neoplasms × ceritinib × Clear all
NCT02186821 2021-04-08

SIGNATURE

Novartis

Phase 2 Terminated
47 enrolled 13 charts
LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡